niacinamide has been researched along with melphalan in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Brown, DM; Brown, JM; Hirst, DG; Horsman, MR | 2 |
| Everett, J | 1 |
| Ali-Osman, F; Augustine, CK; Beasley, GM; Burchette, J; Jung, SH; McMahon, N; Padussis, J; Pruitt, SK; Selim, MA; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA | 1 |
| Augustine, C; Beasley, GM; Brady, MS; Coleman, AP; Davies, MA; Peterson, BL; Raymond, A; Sanders, G; Selim, MA; Tyler, DS | 1 |
1 trial(s) available for niacinamide and melphalan
| Article | Year |
|---|---|
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Extremities; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Melanoma; Melphalan; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Array Analysis; Skin Neoplasms; Sorafenib; Tissue Distribution | 2012 |
5 other study(ies) available for niacinamide and melphalan
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Changes in the response of the RIF-1 tumour to melphalan in vivo induced by inhibitors of nuclear ADP-ribosyl transferase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Body Temperature; Cell Survival; Dose-Response Relationship, Drug; Female; Leukocyte Count; Melphalan; Mice; Mice, Inbred C3H; Niacinamide; Nucleotidyltransferases; Poly(ADP-ribose) Polymerases; Sarcoma, Experimental; Time Factors | 1986 |
Walker carcinosarcoma 256 in study of anticancer agents. II. Results.
Topics: Acetates; Animals; Antineoplastic Agents; Azirines; Benzene; Benzoates; Butyrates; Carcinoma 256, Walker; Glycine; Mannitol; Mechlorethamine; Melphalan; Niacinamide; Oxides; Phthalic Acids; Pyridines; Rats; Sulfhydryl Compounds; Toluene; Xylenes | 1966 |
Enhancement of melphalan cytotoxicity in vivo and in vitro by inhibitors of poly (ADP-ribose) polymerase.
Topics: Animals; Benzamides; Caffeine; Cell Line; Cell Survival; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Melphalan; Mice; Mice, Inbred C3H; NAD+ Nucleosidase; Neoplasm Transplantation; Neoplasms, Experimental; Niacinamide; Poly(ADP-ribose) Polymerase Inhibitors; Time Factors | 1984 |
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Butadienes; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Melanoma; Melphalan; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Nude; Sorafenib; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |